New Hope from an Old Asthma Drug
A common asthma medication used for decades is now drawing attention in cancer research. Scientists found that montelukast, widely prescribed for asthma and allergies, may help the immune system fight some of the hardest-to-treat cancers. Early laboratory and animal studies showed encouraging results against aggressive tumors.
Why Researchers Are Exploring Asthma Drug for Cancer
Montelukast has long been used to reduce inflammation in asthma and allergy patients by blocking leukotrienes—chemicals that trigger inflammation and airway constriction.
Cancer researchers recently discovered that tumors may also exploit these same inflammatory pathways to weaken immune responses. According to early studies, certain cancer cells rely on a receptor called CysLTR1 to create a protective environment against immune attacks. By blocking this receptor with montelukast, researchers observed increased immune cell activity against tumors, suggesting the drug could improve how the immune system responds to difficult cancers.
Why Triple-Negative Breast Cancer Is So Difficult to Treat
Triple-negative breast cancer is considered one of the most aggressive forms because it lacks three common receptors targeted by treatment:
- Estrogen receptors
- Progesterone receptors
- HER2 proteins
Without these receptors, many standard therapies are ineffective. Treatment options are limited to chemotherapy, surgery, radiation, and immunotherapy, with variable outcomes. Some tumors quickly develop resistance, increasing the risk of recurrence. Challenges include faster tumor growth, higher risk of metastasis, greater recurrence rates in early years, and limited targeted treatment options.
How the Asthma Drug Helped in Early Cancer Research
In recent studies, researchers tested montelukast in preclinical cancer models and found that blocking leukotriene signaling appeared to slow tumor growth and improve immune activity around the cancer. Tumors often recruit neutrophils in ways that help cancer survive, but montelukast seemed to disrupt this process.
Researchers believe the treatment may help "reprogram" the tumor environment, allowing immune cells to function more effectively. This could be especially important for immunotherapy-resistant cancers that stop responding to checkpoint inhibitors.
Why Drug Repurposing Is Gaining Momentum
Developing new cancer drugs can take over a decade and cost billions. Drug repurposing offers a faster alternative since existing medications have known safety profiles. Advantages include existing safety and dosage data, lower R&D costs, faster transition to clinical trials, and potentially broader patient access if approved.
Future Outlook and Important Risks
Despite the excitement, experts caution that research is still early. Most data come from lab and animal studies, not large human trials. Many promising treatments in mice fail in humans. Researchers still need to determine which cancers respond best, safe dosages, whether the drug works alone or in combination, and which patients benefit most.
Montelukast also has known side effects. The FDA has warned about possible mental health side effects, including mood changes and sleep disturbances. Experts strongly advise against self-treatment outside clinical supervision.